BMS forms immuno-oncology collaboration with 10 US and EU cancer institutes
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb (BMS) formed the International Immuno-Oncology Network (II-ON) with 10 research centers in the US and EU as a global collaboration between industry and academia to broaden global scientific understanding of how the body's immune system can be harnessed to fight cancer.
You may also be interested in...
Bristol Teams Up With Billionaire-Backed Parker Institute On IO Research
A key goal of Bristol's second major academic research collaboration is to get trials up-and-running more quickly.
Jardiance Improves Double-Digit Growth Potential With US Approval In CKD
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
A Year And A Half After Giving Up On TAK-721, Takeda Seeks Approval In EoE
The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.